Company profile

Myeloid Therapeutics

Privately held: no public share price (Private VC-backed biotech; rebranded as CREATE Medicines in Oct 2025 and raised a $122M Series B in 2026, still privately held. [resolved 2026-08-05 by resolve-null-is-public; source: https://www.prnewswire.com/news-releases/myeloid-therapeutics-rebrands-as-create-medicines-focused-on-transforming-immunotherapy-through-rna-based-in-vivo-multi-immune-programming-302575510.html]) · United States

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
MT-302
Phase 1
TROP2Small molecule
Non-Small Cell Lung Cancer
MT-304
Phase 1
HER2Small molecule
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.